PCL, Inc. (KOSDAQ:241820)
South Korea · Delayed Price · Currency is KRW 6,040.00
-100.00 (-1.63%)
At close: Mar 21, 2025
PCL, Inc. Revenue
PCL, Inc. had revenue of 1.21B KRW in the quarter ending September 30, 2025, with 217.42% growth. This brings the company's revenue in the last twelve months to 4.98B, down -36.79% year-over-year. In the year 2024, PCL, Inc. had annual revenue of 1.25B, down -85.22%.
Revenue (ttm)
4.98B
Revenue Growth
-36.79%
P/S Ratio
3.59
Revenue / Employee
160.74M
Employees
31
Market Cap
17.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.25B | -7.18B | -85.22% |
| Dec 31, 2023 | 8.43B | -28.79B | -77.35% |
| Dec 31, 2022 | 37.22B | -8.93B | -19.35% |
| Dec 31, 2021 | 46.15B | -7.54B | -14.04% |
| Dec 31, 2020 | 53.68B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |